Abstract
Increasing reports suggest that deregulated microRNAs (miRNAs) might provide novel therapeutic targets for cancers. However, the expression and function of miR-300 in osteosarcoma is still unknown. In our study, we found that the expression of miR-300 was up-regulated in osteosarcoma tissues and cells compared with paired adjacent non-tumor bone tissues and osteoblastic cells using RT-qPCR. The enforced expression of miR-300 could promote cell proliferation, invasion and epithelial-mesenchymal transition (EMT). Moreover, we identified that bromodomain-containing protein 7 (BRD7), a new tumor suppressor gene, was a direct target of miR-300. Ectopic expression of BRD7 could significantly inhibit miR-300-promoted proliferation, invasion and EMT. Therefore, our results identify an important role for miR-300 in osteosarcoma through regulating BRD7 expression.
Highlights
Osteosarcoma is the most common primary bone malignancy with high local aggressiveness and rapid metastasizing potential, resulting in poor survival[1,2,3]
We found that the expression of miR-300 was up-regulated in osteosarcoma tissues and cell lines compared with paired adjacent non-tumor bone tissues and osteoblastic cells
We revealed that bromodomain-containing protein 7 (BRD7) was a direct target of miR-300 in osteosarcoma cells
Summary
Osteosarcoma is the most common primary bone malignancy with high local aggressiveness and rapid metastasizing potential, resulting in poor survival[1,2,3]. MiR-300 Promotes Proliferation and Invasion of Osteosarcoma cancer, lung cancer, hepatocellular carcinoma, and breast cancer[20,21,22,23,24]. We showed the expression of miR-300 was increased in osteosarcoma tissues and cell lines compared with paired adjacent nontumor bone tissues and osteoblastic cells. Overexpression of miR-300 promoted cell proliferation and invasion and induce EMT. We revealed that bromodomain-containing protein 7 (BRD7) was a direct target of miR300 in osteosarcoma cells
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
